Yesterday, the first U.S. expert consensus treatment recommendations for adults with severe alopecia areata were published in JAMA Dermatology. Developed by leading dermatologists in partnership with the National Alopecia Areata Foundation (NAAF) and the American Hair Research Society (AHRS), the recommendations provide a clear, evidence-based framework for treating this autoimmune disease. For years, patients and healthcare providers have faced a lack of formal treatment guidance, resulting in variability in care and challenges accessing appropriate treatments. These new recommendations help establish a more consistent approach to care based on the latest scientific evidence and clinical expertise. “This is an important step forward for people living with severe alopecia areata,” said Arash Mostaghimi, MD, MPA, MPH, chair of the expert consensus committee. “For the first time, patients, clinicians, and insurers have clear, expert-driven recommendations that reflect both the latest scientific evidence and the real-world impact of this disease on patients’ lives.” The recommendations identify FDA-approved oral JAK inhibitors as the preferred first-line treatment for adults with severe alopecia areata and provide guidance on treatment duration, switching JAK inhibitor therapies when needed, and the use of additional supportive therapies. Importantly, the recommendations recognize that alopecia areata is about more than hair loss. The expert panel adopted a broader approach to defining disease severity, considering not only scalp hair loss but also factors such as eyebrow and eyelash involvement, treatment response, and the emotional and psychosocial impact of the disease, based on the Alopecia Areata Severity Scale (AASc). The recommendations also emphasize the importance of supportive care, including access to wigs (cranial prostheses), mental health support, and other resources that help individuals manage the day-to-day impact of alopecia areata. For patients and families, the publication represents both progress and validation. It acknowledges the significant burden of alopecia areata and reinforces that people living with the disease deserve comprehensive, evidence-based care. Learn more about the treatment recommendations and what they mean for patients, caregivers and healthcare providers at www.naaf.org/treatment-recs.
